JCOG1211:≤3 cm 磨玻璃影为主肺癌肺段切除术的 3 期验证试验
这项日本多中心、单臂、确证性 3 期试验纳入临床 IA 期、肿瘤直径≤3 cm 且含磨玻璃影(GGO)并以 GGO 为主的非小细胞肺癌患者,方案手术为肺段切除加肺门、叶间及肺内淋巴结清扫。
要点
- 该结果超过预设 87% 阈值,主要终点达到
- 3–4 级早期术后并发症 7 例(2%),无 5 级治疗相关死亡
核心结论
- 对直径≤3 cm、含 GGO 并以 GGO 为主的 NSCLC,肺段切除可考虑作为标准治疗的一部分,即使 GGO 超过 2 cm。
研究设计与样本
- 日本 42 家机构开展的多中心、单臂、确证性 3 期试验,方案手术为肺段切除加肺门、叶间及肺内淋巴结清扫。
- 2013 年 9 月 20 日至 2015 年 11 月 13 日共注册 396 例,其中 357 例接受肺段切除。
- 入组条件为 20–79 岁、ECOG 评分 0 或 1、薄层 CT 确认临床 IA 期、肿瘤直径≤3 cm 且含 GGO 并以其为主。
- 主要终点为 5 年无复发生存(RFS)。
主要发现
- 3–4 级早期术后并发症发生于 7 例(2%),无 5 级治疗相关死亡。
关键数值与推荐
- 入组肿瘤标准:直径≤3 cm,含 GGO 且以 GGO 为主,临床 IA 期。
临床怎么用
- 对≤3 cm、以 GGO 为主的临床 IA 期 NSCLC,可将肺段切除加淋巴结清扫纳入治疗选择并与患者讨论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although segmentectomy is a widely used surgical procedure, lobectomy is the standard procedure for resectable non-small-cell lung cancer (NSCLC). This study aimed to evaluate the efficacy and safety of segmentectomy for NSCLC up to 3 cm in size, including ground-glass opacity (GGO) and predominant GGO. METHODS: A multicentre, single-arm, confirmatory phase 3 trial was conducted across 42 institutions (hospitals, university hospitals, and cancer centres) in Japan. Segmentectomy with hilar, interlobar, and intrapulmonary lymph node dissection was performed as protocol surgery for patients with a tumour diameter of up to 3 cm, including GGO and dominant GGO. Eligible patients were those aged 20-79 years with an Eastern Cooperative Oncology Group performance score of 0 or 1 and clinical stage IA tumour confirmed by thin-sliced CT. The primary endpoint was 5-year relapse-free survival (RFS). This study is registered with the University Hospital Medical Information Network Clinical Trials (UMIN000011819), and is ongoing. FINDINGS: A total of 396 patients were registered from Sept 20, 2013, to Nov 13, 2015, of whom 357 underwent segmentectomy. At a median follow-up of 5·4 years (IQR 5·0-6·0), the 5-year RFS was 98·0% (95% CI 95·9-99·1). This finding exceeded the 87% of the pre-set threshold 5-year RFS and the primary endpoint was met. Grade 3 or 4 early postoperative complications occurred in seven patients (2%), but no grade 5 treatment-related deaths occurred. INTERPRETATION: Segmentectomy should be considered as part of standard treatment for patients with predominantly GGO NSCLC with a tumour size of 3 cm or less in diameter, including GGO even if it exceeds 2 cm. FUNDING: National Cancer Centre Research and Development Fund and Japan Agency for Medical Research and Development.
引用
- Aokage K, Suzuki K, Saji H, et al. Segmentectomy for ground-glass-dominant lung cancer with a tumour diameter of 3 cm or less including ground-glass opacity (JCOG1211): a multicentre, single-arm, confirmatory, phase 3 trial. Lancet Respir Med. 2023. PMID: 36893780. doi:10.1016/S2213-2600(23)00041-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。